Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
NCT05355701 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07799933) administered as a single agent and in combination with other study medicines in people with solid tumors. This study is seeking participants who have an advanced solid tumor with a certain type of abnormal gene called "BRAF" and available treatments are no longer effective in controlling their cancer. All participants in this study will receive PF-07799933. PF-07799933 comes as a tablet to take by mouth, 2 times a day. Depending on the part of the study, participants may also receive another study medicine: * People with melanoma or other solid tumors may also receive binimetinib. Binimetinib comes as a tablet to take by mouth, 2 times a day. * People with colorectal cancer may also receive cetuximab or cetuximab and mFOLFOX6 (Chemotherapy regimen). Cetuximab will be given weekly (or every two weeks) in the clinic as a shot given in the vein or port (intravenous, IV). Participants may receive the study medicines for about 2 years. The study team will monitor how each participant is doing with the study treatment during regular visits at the study clinic.
Conditions Studied
Interventions
- DRUG PF-07799933
- DRUG binimetinib
- DRUG fluorouracil
- BIOLOGICAL cetuximab
- DRUG midazolam
Study Locations (20)
Colorado
- Clinical and Translational Research Center (CTRC) — Aurora
- UCHealth Sue Anschutz-Rodgers Eye Center — Aurora
- University of Colorado Hospital - Anschutz Cancer Pavilion (ACP) — Aurora
- University of Colorado Hospital - Anschutz Inpatient Pavilion (AIP) — Aurora
- University of Colorado Hospital - Anschutz Outpatient Pavilion (AOP) — Aurora
Michigan
- Brigitte Harris Cancer Pavilion — Detroit
- Henry Ford Hospital — Detroit
- Henry Ford Medical Center - Columbus — Novi
- CT Scan and Echo Only: Henry Ford Medical Center-Plymouth — Plymouth
Arkansas
- Highlands Oncology Group — Fayetteville
- Highlands Oncology Group — Rogers
- Highlands Oncology Group — Springdale
Massachusetts
- Brigham and Women's Hospital — Boston
- Dana-Farber Cancer Institute — Boston
- DFCI Chestnut Hill — Newton
Florida
- University of Miami Hospital and Clinics, Sylvester Cancer Center — Miami
- University of Miami Sylvester Comprehensive Cancer Center-The Griffin Research Building — Miami
New York
- MSK David H. Koch Center for Cancer Care — New York
- Memorial Sloan Kettering Cancer Center 53rd street — New York
New Jersey
- MSK Monmouth — Middletown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 267 participants |
| Start Date | 2022-07-05 |
| Est. Completion | 2030-05-06 |
| Phase | Phase 1 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05355701
The ClinicalTrials.gov registry entry for NCT05355701 describes a study currently listed as recruiting. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 267 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 769 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 5 conditions, with Melanoma appearing as the primary indexed condition, and to 5 interventions — of which PF-07799933 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05355701 reports 20 study locations spanning 7 distinct geographic areas — top geographies include Colorado, Michigan, Arkansas. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05355701 about?
NCT05355701 is a clinical study titled "A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.". The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07799933) administered as a single agent and in combination with other study medicines in people with solid tumors. This study is seeking participants who have an advanced solid tumor with a...
What is the current status of trial NCT05355701?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 267 participants. The study started on 2022-07-05. Estimated completion is 2030-05-06.
What conditions does trial NCT05355701 study?
This clinical trial studies the following conditions: Melanoma, Glioma, Thyroid Cancer, Non-Small-Cell Lung Cancer, Advanced Colorectal Cancer (Part 1). These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT05355701?
The interventions under investigation include: PF-07799933 (DRUG), binimetinib (DRUG), fluorouracil (DRUG), cetuximab (BIOLOGICAL), midazolam (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT05355701?
This trial is sponsored by Pfizer, which has 769 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05355701 being conducted?
This trial has 20 study locations across Arkansas, Colorado, Florida, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.